Dr John Haylor BPharm PhD MRPS

Photograph of Dr John Haylor

Academic Unit of Nephrology
Department of Infection and Immunity
The University of Sheffield Medical School
Beech Hill Road
Sheffield
S10 2RX
United Kingdom

Tel: +44 (0)114 271 2563
Fax: +44 (0)114 271 3892
Email: j.l.haylor@sheffield.ac.uk
Secretary - Mrs Sue Clary
Tel: +44 (0)114 226 8961
Email: s.clary@sheffield.ac.uk

Biography

I originally trained as a pharmacist but have worked in both physiology and pharmacology moving to Sheffield in 1980 to help establish a new dual honours degree in pharmacology and chemistry. Under the leadership of Dr Godfrey Collins, helped to develop a very successful pharmacology course taught over some 25 years.

As a kidney physiologist I moved to the renal unit at the Northern General Hospital in 1993 to work with Professor Meguid El Nahas, to develop drugs to slow the progression of chronic kidney disease. A strong research link was also established with Professor Sameh Morcos in Diagnostic Imaging.

I hold the Home Office Licence for animal experimentation in the Academic Unit of Nephrology, being involved in collaborative projects to slow the progression of chronic kidney disease with both Professor ACM Ong and Dr T Johnson. I am interested in science teaching and am a module co-ordinator on the undergraduate medical course.

Research Interests

I have always worked on the kidney, initially in eicosanoid physiology, more recently examining potential therapies to slow renal progression. Six experimental models of chronic kidney disease (CKD) are available and we have previously examined the GH-IGF1 pathway and transglutaminase inhibitors and are currently examining MEK inhibition. Additional techniques have involved an extensive use of the isolated kidney and the development of rat models of chronic allograft nephropathy through kidney transplantation. Work with Diagnostic Imaging has involved studies on the nephrotoxicity of iodine-based contrast agents and the nephrogenic systemic fibrosis induced by gadolinium-based MRI agents.

the role of prostanoids in the control of renal function.
nitric oxide as the mediator of the renal response to insulin-like growth factor I (IGF-I).
the value of recombinant human IGF-I in the treatment of end stage renal disease .
endothelin antagonists as a therapeutic regimen for the treatment of acute renal failure caused by radiocontrast media and study their benefit to hypertensive and polycystic kidney disease.
the benefit of transglutaminase inhibitors in slowing the progression of hypertensive and diabetic kidney disease.

Teaching Interests

I am now involved in organising part of the undergraduate medical course and teach in the areas of renal physiology, endocrinology and immunology. I also teach renal physiology on the Masters course in Clinical Nephrology. An interest in the teaching process and attempts to aid student learning have encouraged me to undertake a Masters degree in education.

Professional Activities

I am a director of the Sheffield Kidney Research Foundation and renal editor for the British Journal of Pharmacology (2006-2009). I am a grant reviewer for Kidney Research UK and manuscript referee for a variety of kidney and pharmacology journals.

Current projects

Proteomic analysis of potential biomarkers of renal disease.
Effect of MEK inhibitors on renal fibrosis.
Effect of ischaemic injury on renal transglutaminase.
Effect of MEK inhibition on chronic allograft nephropathy.
Dotarem and nephrogenic systemic fibrosis.

Key Publications

Haylor J, Dencausse A, Vickers M, Nutter F, Jestin G, Slater D, Idee J-M, Morcos SK. Nephrogenic gadolinium biodistribution following a single injection of Omniscna in the rat. Invest Radiol 2010;45:507-512.
Kuan Y, Surman J, Frystyk J, El Nahas AM, Flyvbjerg A, Haylor JL. Lack of effect of IGF-I on the glomerular filtration rate in non-diabetic patients with advanced chronic kidney disease. Growth Hormone and IGF Research 2009;19:219-225.
Ahmed A, Huang L, Raftery AT, Ahmed AK, Fahmy H, El Nahas AM, Haylor JL. Cyclosporine A sensitizes the kidney to tubulointerstitial fibrosis induced by renal warm ischaemia. Transplantation 2004;77:686-692.
Oldroyd SD, Haylor JL Morcos SK. Bosentan, an orally active endothelin receptor antagonist: Effect on the renal response to contrast media. Radiology 1995;196:661-665.
Burton GA, MacNeil S, de Jonge A, Haylor J. Cyclic GMP release and vasodilatation induced by EDRF and atrial natriuretic factor in the isolated perfused kidney of the rat. Brit J Pharmacol 1990;99:364-368.